Alliance Pharma is pleased to announce the appointment of Weiqing Chen, PhD, to the position of Director, Drug Metabolism. Dr. Chen brings more than 14 years of research and industry experience in drug discovery and development. He established the DMPK (drug metabolism and pharmacokinetic) service capability at a leading CRO in China. While there, he developed stable business relationships with more than 100 clients in US, Europe, Japan, and China. He led the DMPK effort in numerous integrated drug discovery and development programs. He also made significant contributions in designing and managing preclinical DMPK studies for regulatory filings in the US and China. His most recent publication was “Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation,” published in the Drug Metabolism and Disposition Journal.
We are thrilled to welcome Dr. Chen for his expertise in designing and conducting ADME studies, as well as LC-MS/MS method development and sample analysis. Frank Li, PhD, Co-founder and President of Alliance Pharma, acknowledged, “With Weiqing’s many years of DMPK experience, knowledge, and strong leadership, Alliance Pharma will continue to provide clients with the highest level of service.” Dr. Chen is excited to share our passion for providing high-quality DMPK services to the growing needs and expectations of our international clients.